Trial Profile
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Vosaroxin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Sarcoma
- Focus Therapeutic Use
- Acronyms VITAL
- 16 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Apr 2024.
- 18 Sep 2023 Planned End Date changed from 1 Jul 2023 to 1 Jan 2024.
- 28 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.